
Please try another search
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Andrew J. Hirsch | 51 | 2020 | CEO, President & Director |
Kenneth C. Anderson | 71 | 2015 | Co-Founder, Independent Director & Member of Scientific Advisory Board |
Ronald H. W. Cooper | 61 | 2024 | Independent Chairman |
Nathanael S. Gray | - | 2016 | Co-Founder & Member of Scientific Advisory Board |
Christopher J. Kirk | 53 | 2016 | Member of Scientific Advisory Board |
Ross L. Levine | 53 | 2017 | Member of Scientific Advisory Board |
Utpal Koppikar | 54 | 2022 | Independent Director |
Laura Bessen | 61 | 2022 | Independent Director |
Donna Roy Grogan | 68 | 2022 | Independent Director |
Scott A. Armstrong | - | 2017 | Member of Scientific Advisory Board |
Ryan B. Corcoran | - | 2019 | Member of Scientific Advisory Board |
Hagop Youssoufian | 68 | 2023 | Member of Clinical Advisory Board |
Randi Isaacs | 69 | - | Member of Clinical Advisory Board |
Beni B. Wolf | - | - | Member of Clinical Advisory Board |
Christopher J. Bowden | 64 | - | Member of Clinical Advisory Board |
Owen P. Hughes | 50 | 2023 | Independent Director |
Steven L. Hoerter | 54 | 2024 | Independent Director |
Stephen Fawell | 65 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review